NURIX THERAPEUTICS, INC. Current Income Tax Expense (Benefit)
NURIX THERAPEUTICS, INC. (NRIX) reported Current Income Tax Expense (Benefit) of $0 for the 12-month period ending 2023-11-30, per its 10-K filed 2024-02-15.
Discontinued › Expense Statement
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2024-02-15
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2021-02-28 was $71.00K, a 545.45% increase year-over-year.
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2020-11-30 was $100.00K, a 41.52% decline year-over-year.
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2020-08-31 was $0.00, a 100.00% decline year-over-year.
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2020-02-29 was $11.00K.
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2023 was $0.00.
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2021 was $100.00K.
- NURIX THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2020 was -$20.50M, a 10350.00% decline from fiscal 2019.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 9 month | Current Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2023-11-30 | $0.00 10-K · filed 2024-02-15 | |||
| 2022-11-30 | $0.00 10-K · filed 2023-02-09 | |||
| 2021-11-30 | $100.00K 10-K · filed 2023-02-09 | |||
| 2021-02-28 | $71.00K 10-Q · filed 2021-04-13 | $171.00K derived: sum of 2 quarters · filed 2022-01-28 | $171.00K derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-11-30 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $100.00K derived: sum of 2 quarters · filed 2022-01-28 | -$20.50M 10-K · filed 2022-01-28 | |
| 2020-08-31 | $0.00 10-Q · filed 2020-10-14 | -$20.60M 10-Q · filed 2020-10-14 | ||
| 2020-02-29 | $11.00K 10-Q · filed 2021-04-13 | $182.00K derived: sum of 2 quarters · filed 2022-01-28 | $192.00K derived: sum of 3 quarters · filed 2022-01-28 | |
| 2019-11-30 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $181.00K derived: sum of 2 quarters · filed 2022-01-28 | $200.00K 10-K · filed 2022-01-28 | |
| 2019-08-31 | $10.00K 10-Q · filed 2020-10-14 | $29.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |